Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at Guggenheim

Key Points

• Guggenheim reiterated a Buy rating on Neurocrine with a $175 price target (about a 21% upside), while consensus analyst coverage is largely positive with an average target of $182.35 and a "Moderate Buy" rating.
• Q1 results showed strong commercial growth—revenue rose ~28% YoY and net product sales (driven by Ingrezza) increased materially—the stock jumped ~6.8% to $144.24 and management reaffirmed Ingrezza full‑year sales guidance.
• Management is expanding the pipeline and near‑term commercial opportunities via a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR) and has initiated a Phase 2 study of NBI‑1117570 in schizophrenia.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report)'s stock had its "buy" rating reissued by research analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports. They currently have a $175.00 price target on the stock. Guggenheim's price target would suggest a potential upside of 21.33% from the stock's current price.

A number of other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Canaccord Genuity Group lifted their price objective on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a "buy" rating in a research note on Tuesday, April 7th. Royal Bank Of Canada dropped their price objective on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an "outperform" rating for the company in a research note on Thursday, February 12th. Weiss Ratings reissued a "hold (c+)" rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 21st. Finally, Wells Fargo & Company dropped their price objective on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $182.35.

Neurocrine Biosciences Stock Up 6.8%

NASDAQ NBIX traded up $9.18 on Wednesday, reaching $144.24. The company had a trading volume of 848,705 shares, compared to its average volume of 1,145,246. The stock has a market capitalization of $14.51 billion, a PE ratio of 31.02, a price-to-earnings-growth ratio of 0.67 and a beta of 0.34. The firm's 50 day moving average price is $130.37 and its 200 day moving average price is $137.72. Neurocrine Biosciences has a 12 month low of $115.66 and a 12 month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business's revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.69 earnings per share. On average, research analysts expect that Neurocrine Biosciences will post 6.57 EPS for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently made changes to their positions in the company. USA Financial Formulas purchased a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company's stock valued at $26,000 after buying an additional 100 shares during the period. Eastern Bank bought a new stake in shares of Neurocrine Biosciences during the third quarter valued at approximately $27,000. DJE Kapital AG bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $28,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Wedbush raised its price target on NBIX to $176 and kept an "outperform" rating, implying meaningful upside and likely supporting buy-side interest. Benzinga
• Positive Sentiment: Q1 results beat expectations: EPS and revenue topped consensus, net product sales rose ~44% YoY to roughly $811M, and management reaffirmed full-year INGREZZA sales guidance of $2.7–$2.8B — data that directly support valuation and near-term cash flow visibility. Q1 Press Release
• Positive Sentiment: INGREZZA sales were a key driver of the better-than-expected quarter, cited by multiple outlets — supporting the commercial growth story and analyst upgrades. Investing.com
• Positive Sentiment: Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY (crinecerfont) — published in a peer-reviewed journal — should help clinicians reduce steroid burden in CAH patients and may accelerate real-world adoption. PR Newswire - CRENESSITY publication
• Positive Sentiment: Neurocrine announced a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR for hyperphagia in Prader‑Willi), expanding the company's pipeline and near-term commercial opportunities; expected close in Q2 2026. Acquisition announcement
• Neutral Sentiment: Pipeline progress: initiation of a Phase 2 study of NBI-1117570 (M1/M4 agonist) in schizophrenia — a positive clinical update but earlier-stage and longer horizon for value realization. Seeking Alpha - presentation
• Neutral Sentiment: Analyst/market coverage and events: company to present at the Bank of America Health Care Conference (May 12) and several earnings call transcripts/analyst notes are circulating — useful for deeper due diligence but not immediate catalysts. Conference notice

About Neurocrine Biosciences

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.